stock-detail (SNGX)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/20/2017 06:19 am

4/20/2017 06:19 am

4/20/2017 06:19 am

4/20/2017 06:19 am

4/20/2017 06:19 am

4/19/2017 12:19 am

4/19/2017 12:19 am

4/19/2017 12:19 am

4/19/2017 12:19 am

4/19/2017 12:19 am

4/13/2017 12:17 pm

4/12/2017 12:17 am

4/12/2017 12:17 am

4/12/2017 12:17 am

4/12/2017 12:17 am

4/11/2017 12:17 am

SOLIGENIX, INC. Financials

3/31/2017 05:00 pm

Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results

3/27/2017 11:03 am

[PR Newswire] - PRINCETON, N.J., March 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2016. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are extremely pleased with the positive results from the Phase 2 study of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer.